157 related articles for article (PubMed ID: 37037699)
1. In vitro effects of combining Mim8 with factor VIII, FVIIa, and activated prothrombin complex concentrates in thrombin generation assays.
Lund J; Jensen K; Burnier L; Ezban M
J Thromb Haemost; 2023 Jun; 21(6):1493-1502. PubMed ID: 37037699
[TBL] [Abstract][Full Text] [Related]
2. The effect of a next generation factor VIII mimetic bispecific antibody (Mim8) on assays of factor VIII activity and thrombin generation.
Bowyer AE; Kitchen S; Ezban M
J Thromb Haemost; 2023 Mar; 21(3):480-487. PubMed ID: 36696203
[TBL] [Abstract][Full Text] [Related]
3. A novel therapeutic approach combining human plasma-derived Factors VIIa and X for haemophiliacs with inhibitors: evidence of a higher thrombin generation rate in vitro and more sustained haemostatic activity in vivo than obtained with Factor VIIa alone.
Tomokiyo K; Nakatomi Y; Araki T; Teshima K; Nakano H; Nakagaki T; Miyamoto S; Funatsu A; Iwanaga S
Vox Sang; 2003 Nov; 85(4):290-9. PubMed ID: 14633255
[TBL] [Abstract][Full Text] [Related]
4. Thrombin generation potential in the presence of concizumab and rFVIIa, APCC, rFVIII, or rFIX: In vitro and ex vivo analyses.
Kjalke M; Kjelgaard-Hansen M; Andersen S; Hilden I
J Thromb Haemost; 2021 Jul; 19(7):1687-1696. PubMed ID: 33819375
[TBL] [Abstract][Full Text] [Related]
5. Potential role of recombinant factor VIIa as a hemostatic agent.
Hedner U; Erhardtsen E
Clin Adv Hematol Oncol; 2003 Feb; 1(2):112-9. PubMed ID: 16224390
[TBL] [Abstract][Full Text] [Related]
6. A novel next-generation FVIIIa mimetic, Mim8, has a favorable safety profile and displays potent pharmacodynamic effects: Results from safety studies in cynomolgus monkeys.
Lauritzen B; Bjelke M; Björkdahl O; Bloem E; Keane K; Kjalke M; Rossen M; Lippert SL; Weldingh KN; Skydsgaard M; Kjellev S
J Thromb Haemost; 2022 Jun; 20(6):1312-1324. PubMed ID: 35191180
[TBL] [Abstract][Full Text] [Related]
7. History of rFVIIa therapy.
Hedner U
Thromb Res; 2010 Apr; 125 Suppl 1():S4-6. PubMed ID: 20188400
[TBL] [Abstract][Full Text] [Related]
8. FRONTIER1: a partially randomized phase 2 study assessing the safety, pharmacokinetics, and pharmacodynamics of Mim8, a factor VIIIa mimetic.
Lentz SR; Chowdary P; Gil L; Lopez-Jaime FJ; Mahlangu J; Matytsina I; Nielsen AL; Windyga J
J Thromb Haemost; 2024 Apr; 22(4):990-1000. PubMed ID: 38142846
[TBL] [Abstract][Full Text] [Related]
9. Thrombin generation on vascular cells in the presence of factor VIII and/or emicizumab.
Atsou S; Schellenberg C; Lagrange J; Lacolley P; Lenting PJ; Denis CV; Christophe OD; Regnault V
J Thromb Haemost; 2024 Jan; 22(1):112-125. PubMed ID: 37776978
[TBL] [Abstract][Full Text] [Related]
10. Hemophilia and von Willebrand's disease: 2. Management. Association of Hemophilia Clinic Directors of Canada.
CMAJ; 1995 Jul; 153(2):147-57. PubMed ID: 7600466
[TBL] [Abstract][Full Text] [Related]
11. Safety, pharmacokinetics and efficacy of factor VIIa formulated with PEGylated liposomes in haemophilia A patients with inhibitors to factor VIII--an open label, exploratory, cross-over, phase I/II study.
Spira J; Plyushch O; Zozulya N; Yatuv R; Dayan I; Bleicher A; Robinson M; Baru M
Haemophilia; 2010 Nov; 16(6):910-8. PubMed ID: 20491957
[TBL] [Abstract][Full Text] [Related]
12. A factor VIIIa-mimetic bispecific antibody, Mim8, ameliorates bleeding upon severe vascular challenge in hemophilia A mice.
Østergaard H; Lund J; Greisen PJ; Kjellev S; Henriksen A; Lorenzen N; Johansson E; Røder G; Rasch MG; Johnsen LB; Egebjerg T; Lund S; Rahbek-Nielsen H; Gandhi PS; Lamberth K; Loftager M; Andersen LM; Bonde AC; Stavenuiter F; Madsen DE; Li X; Holm TL; Ley CD; Thygesen P; Zhu H; Zhou R; Thorn K; Yang Z; Hermit MB; Bjelke JR; Hansen BG; Hilden I
Blood; 2021 Oct; 138(14):1258-1268. PubMed ID: 34077951
[TBL] [Abstract][Full Text] [Related]
13. Administration of recombinant FVIIa (rFVIIa) to concizumab-dosed monkeys is safe, and concizumab does not affect the potency of rFVIIa in hemophilic rabbits.
Lauritzen B; Olling J; Abel KL; Augustsson C; Balling K; Bjelke M; Hegelund AC; Hilden I
J Thromb Haemost; 2019 Mar; 17(3):460-469. PubMed ID: 30614620
[TBL] [Abstract][Full Text] [Related]
14. Thrombin generation for monitoring hemostatic therapy in hemophilia A: A narrative review.
Verhagen MJA; Valke LLFG; Schols SEM
J Thromb Haemost; 2022 Apr; 20(4):794-805. PubMed ID: 35034413
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor and factor VIIa as therapeutic targets in disorders of hemostasis.
Hedner U; Ezban M
Annu Rev Med; 2008; 59():29-41. PubMed ID: 17845136
[TBL] [Abstract][Full Text] [Related]
16. In vitro evidence of a tissue factor-independent mode of action of recombinant factor VIIa in hemophilia.
Augustsson C; Persson E
Blood; 2014 Nov; 124(20):3172-4. PubMed ID: 25232061
[TBL] [Abstract][Full Text] [Related]
17. A next generation FVIII mimetic bispecific antibody, Mim8, the impact on non-factor VIII related haemostasis assays.
Bowyer AE; Hickey K; Kitchen S; Ezban M
Haemophilia; 2023 Nov; 29(6):1633-1637. PubMed ID: 37824563
[TBL] [Abstract][Full Text] [Related]
18. General haemostatic agents--fact or fiction?
Hedner U
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():33-6. PubMed ID: 12214145
[TBL] [Abstract][Full Text] [Related]
19. Tissue factor pathway inhibitor in activated prothrombin complex concentrates (aPCC) moderates the effectiveness of therapy in some severe hemophilia A patients with inhibitor.
Ogiwara K; Nogami K; Matsumoto T; Shima M
Int J Hematol; 2014; 99(5):577-87. PubMed ID: 24687919
[TBL] [Abstract][Full Text] [Related]
20. A modified thrombin generation assay to evaluate the plasma coagulation potential in the presence of emicizumab, the bispecific antibody to factors IXa/X.
Ogiwara K; Nogami K; Matsumoto N; Noguchi-Sasaki M; Hirata M; Soeda T; Shima M
Int J Hematol; 2020 Nov; 112(5):621-630. PubMed ID: 32748217
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
